Stammdaten
Travere Therapeutics, Inc., ein Biopharmaka-Unternehmen, konzentriert sich auf Identifikation, Entwicklung, Kommerzialisierung und Bereitstellung von Therapien zur Behandlung seltener Erkrankungen. Die vermarkteten Produkte des Unternehmens umfassen Chenodal, eine synthetische orale Darreichungsform von Chenodesoxycholsäure zur Behandlung von radiodichten Steinen in Gallenblasen; Cholbam, eine Cholsäure-Kapsel zur Behandlung von pädiatrischen und erwachsenen Patienten mit Störungen der Gallensäuresynthese aufgrund von Einzelenzymdefekten sowie zur adjuvanten Behandlung von Patienten mit peroxisomalen Störungen; sowie Thiola und Thiola EC, eine Tiopronin-Tablette zur Behandlung von homozygöser Cystinurie. Die Produktkandidaten des Unternehmens umfassen ferner Sparsentan, das sich in Phase-III-Studien zur Behandlung von fokal segmentaler Glomerulosklerose und IgA-Nephropathie befindet; sowie TVT-058, ein neuartiger humaner Enzymersatz-Kandidat in Phase-I/II-Studien zur Behandlung der klassischen Homocystinurie. Das Unternehmen hat eine Kooperations- und Entwicklungsvereinbarung mit dem National Center for Advancing Translational Sciences der National Institutes of Health sowie mit Patientenvertretungsorganisationen CDG Care und Alagille Syndrome Alliance zur Identifikation potenzieller Small-Molecule-Therapeutika für NGLY1-Mangel und Alagille-Syndrom. Das Unternehmen war ursprünglich unter dem Namen Retrophin, Inc. bekannt und änderte seinen Namen im November 2020 zu Travere Therapeutics, Inc. Travere Therapeutics, Inc. wurde 2008 gegründet und hat seinen Sitz in San Diego, Kalifornien. KI
Unternehmen & Branche
| Name | Travere Therapeutics, Inc. |
|---|---|
| Ticker | TVTX |
| CIK | 0001438533 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 89422G107 |
|---|---|
| ISIN | US89422G1076 |
| Typ | Common Stock |
| Marktkapitalisierung | 5,04 Mrd. USD |
| Beta | 1,10 |
Sitz & Kontakt
| Sitz (Inkorporation) | CA |
|---|---|
| Geschäftsadresse | 3611 VALLEY CENTRE DR SUITE 300, 92130 SAN DIEGO, CA |
| Telefon | 888-969-7879 |
| EIN (IRS) | 26-2383102 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | Retrophin, Inc. (bis 2020) Desert Gateway, Inc. (bis 2013) |
Bewertung
| KBV (P/B) | 43,92 vs. 6,42 (2021) ▲ |
|---|---|
| KUV (P/S) | 10,28 vs. 14,71 (2021) ▼ |
| FCF-Rendite | 0,7 % vs. -1,0 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 97,9 % vs. 97,1 % (2021) ≈ |
|---|---|
| Operative Marge | -12,8 % vs. -151,3 % (2021) ▲ |
| Nettomarge | -5,2 % vs. -136,6 % (2021) ▲ |
| ROIC | -19,4 % vs. -53,4 % (2021) ▲ |
| Zinsdeckungsgrad | -5,8 vs. -10,1 (2021) ▲ |
| Forderungslaufzeit (DSO) | 60 T vs. 44 T (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 6,42 | 31,55 | 3,37 | 25,79 | 30,26 | 51,08 | |
| KUV (P/S) | 14,71 | 12,35 | 4,67 | 6,53 | 7,08 | 9,41 | |
| FCF-Rendite | -1,0 % | -13,8 % | -41,4 % | -15,6 % | 1,1 % | 0,8 % | |
| Qualität & Bilanz | |||||||
| Bruttomarge | 97,1 % | 96,0 % | 92,1 % | 96,7 % | 97,9 % | 98,6 % | |
| Operative Marge | -151,3 % | -292,2 % | -267,2 % | -138,9 % | -12,8 % | -10,6 % | |
| Nettomarge | -136,6 % | -254,4 % | -76,7 % | -137,9 % | -5,2 % | -4,0 % | |
| ROIC | -53,4 % | -372,3 % | -48,8 % | -393,7 % | -19,4 % | -18,7 % | |
| Zinsdeckungsgrad | -10,1 | -29,1 | -34,3 | -29,0 | -5,8 | -5,6 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
TVTX
Travere Therapeutics, Inc.
Effektiv
Neutral
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
44,2
50 neu, 101 erhöht, -1113950K $ netto
Aktivist
23,8
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 50.96 | +11.0 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 37.12 | +52.4 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 55.82 | EMA50: 51.36 | |
| MACD-Histogramm | Bärisch | 10 % | -0.633 | Bearisch | |
| RSI(14) | Neutral | 10 % | 56.7 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 53.5 | Neutral | |
| ADX(14)+DI | Bärisch | 10 % | 28.6 | +DI: 19.2 / −DI: 21.2 | |
| Z-Score(60) | Neutral | 5 % | 1.11 | In Range | |
| 52W-Position | Bullisch | 5 % | 94.4 % | Hoch 59.03 / Tief 15.32 | |
| Bollinger(20,2σ) | Neutral | 5 % | 36.7 % | Upper 59.24 / Mid 57.14 / Lower 55.03 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.3374 | R²=0.85 / annualisiert +171.6 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | Coughlin Timothy | Director | Open Market Sale | -10.000 | 50,07 | -500.747,00 | -105,5% | |
| 2026-06-12 | Baynes Roy D. | Director | Open Market Sale | -4.500 | 50,00 | -225.000,00 | -47,4% | |
| 2026-05-15 | Coughlin Timothy | Director | Open Market Sale | -3.250 | 43,49 | -141.342,50 | -29,8% | |
| 2026-05-06 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -22.500 | 43,95 | -988.875,00 | -208,3% | |
| 2026-05-06 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -310 | 43,95 | -13.624,50 | -2,9% | |
| 2026-05-06 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -311 | 43,95 | -13.668,45 | -2,9% | |
| 2026-05-06 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -2.076 | 43,95 | -91.240,20 | -19,2% | |
| 2026-05-06 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -2.763 | 43,95 | -121.433,85 | -25,6% | |
| 2026-05-05 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2.181 | 46,65 | -101.743,65 | -21,4% | |
| 2026-05-05 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -2.174 | 46,65 | -101.417,10 | -21,4% | |
| 2026-05-05 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.174 | 46,65 | -101.417,10 | -21,4% | |
| 2026-05-05 | Baynes Roy D. | Director | Open Market Sale | -4.500 | 46,65 | -209.925,00 | -44,2% | |
| 2026-05-05 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -2.174 | 46,65 | -101.417,10 | -21,4% | |
| 2026-05-04 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -20.000 | 45,00 | -900.000,00 | -189,6% | |
| 2026-05-04 | Meckler Jeffrey A | Director | Open Market Sale | -8.000 | 45,00 | -360.000,00 | -75,8% | |
| 2026-05-04 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -20.000 | 45,00 | -900.000,00 | -189,6% | |
| 2026-05-01 | Baynes Roy D. | Director | Open Market Sale | -9.750 | 44,22 | -431.145,00 | -90,8% | |
| 2026-04-22 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -9.100 | 39,09 | -355.719,00 | -74,9% | |
| 2026-04-15 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -56.815 | 41,01 | -2.329.983,15 | -490,9% | |
| 2026-04-15 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -20 | 42,66 | -853,20 | -0,2% | |
| 2026-04-15 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.018 | 42,61 | -43.376,98 | -9,1% | |
| 2026-04-15 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.014 | 42,61 | -43.206,54 | -9,1% | |
| 2026-04-15 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -1.559 | 42,53 | -66.304,27 | -14,0% | |
| 2026-04-15 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -5.226 | 41,62 | -217.506,12 | -45,8% | |
| 2026-04-15 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7.165 | 41,75 | -299.138,75 | -63,0% | |
| 2026-04-14 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -7.215 | 41,93 | -302.516,29 | -63,7% | |
| 2026-04-14 | Baynes Roy D. | Director | Open Market Sale | -26.000 | 41,07 | -1.067.820,00 | -225,0% | |
| 2026-04-14 | Baynes Roy D. | Director | Open Market Sale | -6.750 | 42,12 | -284.310,00 | -59,9% | |
| 2026-04-14 | LYONS GARY A | Director | Open Market Sale | -8.000 | 41,07 | -328.560,00 | -69,2% | |
| 2026-04-14 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -21.977 | 41,07 | -902.595,39 | -190,2% | |
| 2026-04-14 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -7.215 | 41,93 | -302.516,29 | -63,7% | |
| 2026-04-14 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -7.215 | 41,93 | -302.516,29 | -63,7% | |
| 2026-04-14 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -7.239 | 41,93 | -303.522,58 | -63,9% | |
| 2026-04-14 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -9 | 41,07 | -369,63 | -0,1% | |
| 2026-04-14 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -37.500 | 41,07 | -1.540.125,00 | -324,5% | |
| 2026-04-13 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -65 | 28,85 | -1.875,25 | -0,4% | |
| 2026-04-06 | Baynes Roy D. | Director | Open Market Sale | -10.000 | 33,00 | -330.000,00 | -69,5% | |
| 2026-04-01 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -25.098 | 31,46 | -789.583,08 | -166,3% | |
| 2026-04-01 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -34.902 | 30,55 | -1.066.256,10 | -224,6% | |
| 2026-04-01 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10.000 | 30,00 | -300.000,00 | -63,2% | |
| 2026-03-16 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10.000 | 28,09 | -280.861,00 | -59,2% | |
| 2026-02-20 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -60.000 | 30,10 | -1.805.766,00 | -380,4% | |
| 2026-02-17 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -5.679 | 27,50 | -156.195,22 | -32,9% | |
| 2026-02-17 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -4.321 | 28,26 | -122.120,10 | -25,7% | |
| 2026-02-04 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -110 | 32,90 | -3.619,00 | -0,8% | |
| 2026-02-04 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -509 | 32,74 | -16.664,66 | -3,5% | |
| 2026-02-04 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -2.485 | 32,07 | -79.693,95 | -16,8% | |
| 2026-02-04 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.547 | 32,11 | -49.674,17 | -10,5% | |
| 2026-02-04 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -232 | 32,85 | -7.621,20 | -1,6% | |
| 2026-02-04 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.635 | 32,14 | -52.548,90 | -11,1% | |
| 2026-02-03 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -7.175 | 32,12 | -230.461,00 | -48,6% | |
| 2026-02-03 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -12.446 | 32,87 | -409.100,02 | -86,2% | |
| 2026-02-03 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -66.452 | 32,06 | -2.130.451,12 | -448,8% | |
| 2026-02-03 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -33.635 | 32,70 | -1.099.864,50 | -231,7% | |
| 2026-02-03 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -4.333 | 32,12 | -139.175,96 | -29,3% | |
| 2026-02-03 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -7.310 | 32,12 | -234.797,20 | -49,5% | |
| 2026-02-03 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -6.956 | 32,12 | -223.426,72 | -47,1% | |
| 2026-02-03 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -7.242 | 32,12 | -232.613,04 | -49,0% | |
| 2026-01-27 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -51.865 | 30,10 | -1.560.980,91 | -328,9% | |
| 2026-01-23 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -8.135 | 30,01 | -244.153,31 | -51,4% | |
| 2026-01-20 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10.000 | 27,34 | -273.420,00 | -57,6% | |
| 2026-01-06 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -445 | 37,75 | -16.798,75 | -3,5% | |
| 2026-01-05 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.031 | 40,18 | -81.605,58 | -17,2% | |
| 2025-12-24 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -15.000 | 42,00 | -630.004,50 | -132,7% | |
| 2025-12-24 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -7.402 | 40,00 | -296.080,00 | -62,4% | |
| 2025-12-24 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -60.000 | 40,10 | -2.406.180,00 | -506,9% | |
| 2025-12-24 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -4.980 | 40,00 | -199.200,00 | -42,0% | |
| 2025-12-15 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -2.910 | 36,00 | -104.760,00 | -22,1% | |
| 2025-12-01 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -20.000 | 35,01 | -700.202,00 | -147,5% | |
| 2025-11-04 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -67.115 | 36,00 | -2.416.140,00 | -509,0% | |
| 2025-10-31 | Coughlin Timothy | Director | Open Market Sale | -18.000 | 35,03 | -630.601,20 | -132,8% | |
| 2025-10-31 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -5.591 | 35,00 | -195.685,00 | -41,2% | |
| 2025-10-29 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -27.128 | 30,12 | -817.073,66 | -172,1% | |
| 2025-10-28 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -2.662 | 30,00 | -79.860,00 | -16,8% | |
| 2025-10-28 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -92.872 | 30,38 | -2.821.358,49 | -594,4% | |
| 2025-09-22 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10.000 | 25,00 | -250.000,00 | -52,7% | |
| 2025-09-04 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -119 | 19,71 | -2.345,49 | -0,5% | |
| 2025-09-03 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -454 | 18,20 | -8.262,80 | -1,7% | |
| 2025-08-27 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -470 | 17,31 | -8.135,70 | -1,7% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1932 von typischerweise 8378 Fonds (23 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Janus Henderson Group Ltd. | 16.198.586 | 0 | 16.198.586 | 345.282.722 | Neu | +100,0% | |
| FMR LLC | 21.819.967 | 0 | 21.819.967 | 339.540.480 | Neu | +100,0% | |
| BlackRock, Inc. | 12.767.033 | 0 | 12.767.033 | 237.773.779 | Neu | +100,0% | |
| STATE STREET CORP | 4.959.988 | 0 | 4.959.988 | 147.361.243 | Neu | +100,0% | |
| ARMISTICE CAPITAL, LLC | 4.897.417 | 0 | 4.897.417 | 145.502.259 | Neu | +100,0% | |
| LINDEN ADVISORS LP | 101.062.000 | 0 | 101.062.000 | 127.919.176 | Neu | +100,0% | |
| PERCEPTIVE ADVISORS LLC | 4.142.551 | 0 | 4.142.551 | 123.075.190 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.045.812 | 0 | 4.045.812 | 120.201.075 | Neu | +100,0% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3.270.513 | 0 | 3.270.513 | 97.167.000 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 39.121.544 | 0 | 39.121.544 | 73.212.178 | Neu | +100,0% | |
| Kynam Capital Management, LP | 2.423.918 | 0 | 2.423.918 | 72.014.604 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.369.559 | 0 | 2.369.559 | 70.411.435 | Neu | +100,0% | |
| Context Capital Management, LLC | 52.933.000 | 0 | 52.933.000 | 66.936.425 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 1.966.779 | 0 | 1.966.779 | 58.433.004 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 6.402.721 | 0 | 6.402.721 | 56.997.236 | Neu | +100,0% | |
| Stephens Investment Management Group LLC | 1.798.466 | 0 | 1.798.466 | 53.432.425 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 4.508.259 | 0 | 4.508.259 | 48.592.775 | Neu | +100,0% | |
| EMERALD ADVISERS, LLC | 1.557.196 | 0 | 1.557.196 | 46.264.293 | Neu | +100,0% | |
| Rock Springs Capital Management LP | 1.477.954 | 0 | 1.477.954 | 43.910.013 | Neu | +100,0% | |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 32.000.000 | 0 | 32.000.000 | 40.446.334 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 1.345.111 | 0 | 1.345.111 | 39.963.238 | Neu | +100,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.282.518 | 0 | 1.282.518 | 38.103.610 | Neu | +100,0% | |
| MPM BioImpact LLC | 1.133.365 | 0 | 1.133.365 | 33.672.274 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.093.858 | 0 | 1.093.858 | 32.498.521 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 1.022.272 | 0 | 1.022.272 | 30.371.701 | Neu | +100,0% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 977.000 | 0 | 977.000 | 29.026.670 | Neu | +100,0% | |
| EMERALD MUTUAL FUND ADVISERS TRUST | 945.033 | 0 | 945.033 | 28.076.930 | Neu | +100,0% | |
| Nuveen, LLC | 938.569 | 0 | 938.569 | 27.884.885 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 925.919 | 0 | 925.919 | 27.509.054 | Neu | +100,0% | |
| UBS Group AG | 2.083.757 | 0 | 2.083.757 | 27.001.252 | Neu | +100,0% | |
| Fiera Capital Corp | 900.868 | 0 | 900.868 | 26.764.789 | Neu | +100,0% | |
| BARCLAYS PLC | 1.109.461 | 0 | 1.109.461 | 25.848.534 | Neu | +100,0% | |
| Caption Management, LLC | 864.500 | 0 | 864.500 | 25.684.295 | Neu | +100,0% | |
| Assenagon Asset Management S.A. | 427.305 | 7.927 | 419.378 | 24.275.197 | Aufgestockt | +5290,5% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 790.812 | 0 | 790.812 | 23.495.025 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 781.418 | 0 | 781.418 | 23.215.929 | Neu | +100,0% | |
| RA CAPITAL MANAGEMENT, L.P. | 746.841 | 0 | 746.841 | 22.188.646 | Neu | +100,0% | |
| ADVENT CAPITAL MANAGEMENT /DE/ | 17.392.000 | 0 | 17.392.000 | 22.025.649 | Neu | +100,0% | |
| Ensign Peak Advisors, Inc | 715.707 | 0 | 715.707 | 21.263.655 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 669.159 | 0 | 669.159 | 19.880.714 | Neu | +100,0% | |
| PANAGORA ASSET MANAGEMENT INC | 592.912 | 0 | 592.912 | 17.615.416 | Neu | +100,0% | |
| Aberdeen Group plc | 557.147 | 0 | 557.147 | 16.552.837 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 842.380 | 0 | 842.380 | 16.494.207 | Neu | +100,0% | |
| Soleus Capital Management, L.P. | 546.000 | 0 | 546.000 | 16.221.660 | Neu | +100,0% | |
| Eversept Partners, LP | 542.610 | 0 | 542.610 | 16.120.943 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 529.757 | 0 | 529.757 | 14.678.636 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 480.664 | 0 | 480.664 | 14.280.528 | Neu | +100,0% | |
| Legal & General Group Plc | 451.056 | 0 | 451.056 | 13.400.874 | Neu | +100,0% | |
| SHENKMAN CAPITAL MANAGEMENT INC | 9.662.000 | 0 | 9.662.000 | 12.442.328 | Neu | +100,0% | |
| HSBC HOLDINGS PLC | 396.853 | 0 | 396.853 | 11.788.116 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1932 von typischerweise 8378 Fonds (23 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Assenagon Asset Management S.A. | 427.305 | 7.927 | +5290,5% | 24.275.197 | 59,62 | 100 % | 17 Q |
| Hennion & Walsh Asset Management, Inc. | 171.470 | 113.511 | +51,1% | 9.741.211 | 23,92 | 100 % | 15 Q |
| OAK RIDGE INVESTMENTS LLC | 52.234 | 67.323 | -22,4% | 2.967.414 | 7,29 | 88 % | 17 Q |
| Diversified Trust Co | 35.281 | 28.161 | +25,3% | 2.004.313 | 4,92 | 0 % | 9 Q |
| HIGHLAND CAPITAL MANAGEMENT, LLC | 8.701 | 0 | +100,0% | 494.304 | 1,21 | 100 % | 1 Q |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 6.445 | 0 | +100,0% | 364.705 | 0,90 | 6 % | 5 Q |
| Mirae Asset Global Investments Co., Ltd. | 4.159 | 4.811 | -13,6% | 236.273 | 0,58 | 100 % | 17 Q |
| LANARK FINANCIAL, INC. | 3.853 | 0 | +100,0% | 218.888 | 0,54 | 100 % | 8 Q |
| IFP Advisors, Inc | 2.240 | 2.298 | -2,5% | 127.254 | 0,31 | 100 % | 7 Q |
| FIRST HORIZON CORP | 2.161 | 2.942 | -26,5% | 122.767 | 0,30 | 100 % | 4 Q |
| Versant Capital Management, Inc | 611 | 611 | 0,0% | 34.711 | 0,09 | 100 % | 9 Q |
| GAMMA Investing LLC | 606 | 395 | +53,4% | 34.427 | 0,08 | 100 % | 10 Q |
| Spire Wealth Management | 600 | 0 | +100,0% | 34.086 | 0,08 | – | 1 Q |
| EASTERN BANK | 325 | 325 | 0,0% | 18.463 | 0,05 | 100 % | 2 Q |
| Farther Finance Advisors, LLC | 301 | 337 | -10,7% | 17.165 | 0,04 | 0 % | 11 Q |
| MassMutual Private Wealth & Trust, FSB | 244 | 235 | +3,8% | 13.862 | 0,03 | 100 % | 11 Q |
| True Wealth Design, LLC | 62 | 62 | 0,0% | 3.523 | 0,01 | 0 % | 7 Q |
| Ares Financial Consulting, LLC | 49 | 0 | +100,0% | 2.784 | 0,01 | 100 % | 1 Q |
| SJS Investment Consulting Inc. | 44 | 14 | +214,3% | 2.500 | 0,01 | 0 % | 3 Q |
| Handelsbanken Fonder AB | 37.000 | 0 | +100,0% | 2.102 | 0,01 | 0 % | 7 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 24 | 0,8 | 41 |
| 31.03.2026 | ✓ | 271 | 426,5 | 3.926 |
| 31.12.2025 | ✓ | 290 | 429,6 | 4.437 |
| 30.09.2025 | ✓ | 249 | 355,8 | 2.783 |
| 30.06.2025 | ✓ | 223 | 400,9 | 1.788 |
| 31.03.2025 | ✓ | 235 | 456,7 | 2.243 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 4.045.812 | 120.201.075 |
| MPM BioImpact LLC | 1.133.365 | 33.672.274 |
| RA CAPITAL MANAGEMENT, L.P. | 746.841 | 22.188.646 |
| Soleus Capital Management, L.P. | 546.000 | 16.221.660 |
| HSBC HOLDINGS PLC | 396.853 | 11.788.116 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 214.925 | 5.944.826 |
| CenterBook Partners LP | 157.122 | 4.668.095 |
| Ishara Investments LP | 110.700 | 3.288.897 |
| CAPITAL FUND MANAGEMENT S.A. | 85.881 | 2.551.524 |
| Empowered Funds, LLC | 84.820 | 2.520.002 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| TENOR CAPITAL MANAGEMENT Co., L.P. | 32.000.000 | 18.240.000 | +132.6 % | 40.446.334 |
| LINDEN ADVISORS LP | 101.062.000 | 15.500.000 | +18.1 % | 127.919.176 |
| Janus Henderson Group Ltd. | 16.198.586 | 5.687.420 | +54.1 % | 345.282.722 |
| TWO SIGMA INVESTMENTS, LP | 4.508.259 | 3.351.452 | +289.7 % | 48.592.775 |
| ADVENT CAPITAL MANAGEMENT /DE/ | 17.392.000 | 3.180.000 | +22.4 % | 22.025.649 |
| SHENKMAN CAPITAL MANAGEMENT INC | 9.662.000 | 3.000.000 | +45.0 % | 12.442.328 |
| UBS Group AG | 2.083.757 | 1.661.138 | +393.1 % | 27.001.252 |
| BlackRock, Inc. | 12.767.033 | 1.222.681 | +10.6 % | 237.773.779 |
| JPMORGAN CHASE & CO | 2.085.551 | 1.168.936 | +127.5 % | 10.165.968 |
| ARMISTICE CAPITAL, LLC | 4.897.417 | 1.133.526 | +30.1 % | 145.502.259 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| FMR LLC | 21.819.967 | -18.059.896 | -45.3 % | 339.540.480 |
| Affinity Asset Advisors, LLC | 300.000 | -7.000.000 | -95.9 % | 8.913.000 |
| Context Capital Management, LLC | 52.933.000 | -4.524.000 | -7.9 % | 66.936.425 |
| LORD, ABBETT & CO. LLC | 9.078.000 | -4.509.822 | -33.2 % | 11.461 |
| MORGAN STANLEY | 301.655 | -2.419.242 | -88.9 % | 8.962.172 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 977.000 | -1.950.000 | -66.6 % | 29.026.670 |
| GOLDMAN SACHS GROUP INC | 6.402.721 | -1.400.491 | -17.9 % | 56.997.236 |
| Kohlberg Kravis Roberts & Co. L.P. | 860.000 | -1.135.000 | -56.9 % | 1.087.513 |
| NEW YORK STATE COMMON RETIREMENT FUND | 293.357 | -756.200 | -72.0 % | 8.715.636 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 114.268 | -753.354 | -86.8 % | 3.394.902 |
Zusätzlich aktuell von 168 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 15.05.2026 | Armistice Capital, LLC (+1) | Passiv (13G) | 5,27 % | 4.897.417 | +1,06 pp | |
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,09 % | 4.699.424 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -6,74 pp | |
| 17.02.2026 | Perceptive Life Sciences Master Fund, Ltd. (+2) | Passiv (13G/A) | 4,80 % | 4.278.180 | -0,70 pp | |
| 17.02.2026 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 4,21 % | 3.763.891 | -3,31 pp | |
| 13.02.2026 | Macquarie Investment Management Business Trust (+2) | Passiv (13G/A) | Ausstieg | 0 | -5,41 pp | |
| 09.02.2026 | STATE STREET CORPORATION | Passiv (13G) | 5,30 % | 4.756.666 | +1,70 pp | |
| 08.01.2026 | Abigail P. Johnson (+1) | Passiv (13G) | 11,70 % | 10.567.303 | Neu | |
| 14.11.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 11,90 % | 10.599.660 | -0,90 pp | |
| 14.11.2025 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 7,52 % | 6.724.000 | -2,44 pp | |
| 14.10.2025 | Perceptive Life Sciences Master Fund, Ltd. (+2) | Passiv (13G) | 5,50 % | 4.895.615 | +2,50 pp | |
| 15.08.2025 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 9,96 % | 8.876.000 | -0,03 pp | |
| 07.08.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 12,80 % | 11.339.864 | +4,30 pp | |
| 29.07.2025 | The Vanguard Group | Passiv (13G/A) | 6,74 % | 5.994.283 | +1,09 pp | |
| 15.05.2025 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 9,99 % | 8.872.000 | +0,37 pp | |
| 15.05.2025 | Rock Springs Capital Master Fund LP | Passiv (13G/A) | 2,60 % | 2.327.521 | -2,21 pp | |
| 15.05.2025 | Rock Springs Capital Management LP (+3) | Passiv (13G/A) | 3,30 % | 2.921.196 | -2,42 pp | |
| 15.05.2025 | Macquarie Investment Management Business Trust (+2) | Passiv (13G/A) | 5,41 % | 4.797.314 | +0,51 pp | |
| 14.05.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G) | 8,50 % | 7.566.963 | Neu | |
| 30.04.2025 | The Vanguard Group | Passiv (13G/A) | 5,65 % | 5.014.020 | -2,10 pp | |
| 17.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 7,50 % | 6.689.435 | -1,90 pp | |
| 14.02.2025 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 9,62 % | 7.358.000 | -0,38 pp | |
| 14.02.2025 | Rock Springs Capital Master Fund LP | Passiv (13G/A) | 4,81 % | 4.180.000 | -0,22 pp | |
| 14.02.2025 | Rock Springs Capital Management LP (+3) | Passiv (13G/A) | 5,72 % | 4.973.649 | -0,07 pp | |
| 14.02.2025 | Woodline Partners LP | Passiv (13G/A) | 2,40 % | 2.114.056 | -3,30 pp | |
| 07.02.2025 | Macquarie Investment Management Business Trust (+2) | Passiv (13G/A) | 4,90 % | 4.259.557 | -0,64 pp | |
| 05.02.2025 | BlackRock, Inc. | Passiv (13G/A) | 9,40 % | 8.018.292 | Neu | |
| 31.01.2025 | The Vanguard Group | Passiv (13G/A) | 7,75 % | 6.742.165 | -1,27 pp | |
| 14.11.2024 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 10,00 % | 7.648.000 | +0,17 pp | |
| 14.11.2024 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G/A) | 0,70 % | 531.857 | -9,29 pp | |
| 14.11.2024 | Woodline Partners LP | Passiv (13G) | 5,70 % | 4.340.340 | Neu | |
| 12.11.2024 | The Vanguard Group | Passiv (13G/A) | 9,02 % | 6.902.150 | 0,00 pp | |
| 08.11.2024 | Morgan Stanley | Passiv (13G/A) | 1,70 % | 1.319.809 | -3,80 pp | |
| 04.11.2024 | The Vanguard Group | Passiv (13G/A) | 9,02 % | 6.902.150 | +1,68 pp | |
| 18.10.2024 | STATE STREET CORPORATION | Passiv (13G/A) | 3,60 % | 2.736.696 | Neu | |
| 01.05.2024 | Rock Springs Capital Master Fund LP | Passiv (13G) | 5,03 % | 3.828.765 | Neu | |
| 01.05.2024 | Rock Springs Capital Management LP (+1) | Passiv (13G) | 5,79 % | 4.411.983 | Neu | |
| 14.02.2024 | Macquarie Investment Management Business Trust (+2) | Passiv (13G/A) | 6,31 % | 4.746.144 | Neu | |
| 14.02.2024 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 9,83 % | 7.384.000 | -0,16 pp | |
| 14.02.2024 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G/A) | 9,99 % | 7.522.281 | +2,85 pp |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 127.199.000 $ | -37.102.000 $ | -0,40 $ | 555.188.000 $ | 98.728.000 $ |
| 2025-12-31 | 10-K | 490.728.000 $ | -25.546.000 $ | -0,29 $ | 605.191.000 $ | 114.828.000 $ |
| 2025-09-30 | 10-Q | 164.859.000 $ | 25.706.000 $ | 0,28 $ | 538.581.000 $ | 73.564.000 $ |
| 2025-06-30 | 10-Q | 114.449.000 $ | -12.755.000 $ | -0,14 $ | 555.309.000 $ | 32.747.000 $ |
| 2025-05-31 | 10-K | 17.500.000 $ | – | – | – | – |
| 2025-05-31 | 10-Q | 17.500.000 $ | – | – | – | – |
| 2025-03-31 | 10-Q | 81.732.000 $ | -41.226.000 $ | -0,47 $ | 548.799.000 $ | 32.823.000 $ |
| 2024-12-31 | 10-K | 233.175.000 $ | -321.545.000 $ | -4,08 $ | 594.125.000 $ | 59.077.000 $ |
| 2024-09-30 | 10-Q | 62.898.000 $ | -54.811.000 $ | -0,70 $ | 504.410.000 $ | -30.454.000 $ |
| 2024-06-30 | 10-Q | 54.116.000 $ | -70.409.000 $ | -0,91 $ | 551.121.000 $ | 15.147.000 $ |
| 2024-03-31 | 10-Q | 41.374.000 $ | -136.061.000 $ | -1,76 $ | 663.547.000 $ | 74.071.000 $ |
| 2024-01-31 | 10-K | 8.300.000 $ | – | – | – | – |
| 2024-01-31 | 10-Q | 8.300.000 $ | – | – | – | – |
| 2023-12-31 | 10-K | 145.238.000 $ | -111.399.000 $ | -1,50 $ | 788.913.000 $ | 200.810.000 $ |
| 2023-09-30 | 10-Q | 37.095.000 $ | 150.735.000 $ | 1,97 $ | 832.850.000 $ | 279.766.000 $ |
| 2023-06-30 | 10-Q | 32.196.000 $ | -85.630.000 $ | -1,13 $ | 736.429.000 $ | 116.485.000 $ |
| 2023-03-31 | 10-Q | 30.888.000 $ | -86.331.000 $ | -1,27 $ | 808.231.000 $ | 189.140.000 $ |
| 2022-12-31 | 10-K | 109.460.000 $ | -278.482.000 $ | -4,37 $ | 672.585.000 $ | 42.851.000 $ |
| 2022-09-30 | 10-Q | 28.075.000 $ | -69.656.000 $ | -1,09 $ | 726.215.000 $ | 100.676.000 $ |
| 2022-06-30 | 10-Q | 54.167.000 $ | -67.032.000 $ | -1,05 $ | 779.494.000 $ | 156.713.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 410,5 Mio. | 226,7 Mio. | 127,5 Mio. | 200,5 Mio. | 210,8 Mio. | 45,5 % | +81,1% | |
| FILSPARI | 322,0 Mio. | 132,2 Mio. | 29,2 Mio. | – | – | 35,7 % | +143,5% | |
| Tiopronin Products | 88,5 Mio. | 94,5 Mio. | 98,3 Mio. | 98,0 Mio. | 115,1 Mio. | 9,8 % | -6,4% | |
| License | 80,3 Mio. | 6,5 Mio. | 17,7 Mio. | 11,5 Mio. | 16,7 Mio. | 8,9 % | +1141,0% | |
| Clinical Development Activity | – | – | 14,4 Mio. | – | – | – | – | |
| Active Pharmaceutical Ingredient | – | – | 3,3 Mio. | – | – | – | – | |
| Bile Acid Products | – | – | – | 102,6 Mio. | 95,7 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 04.05.2026 | 127,2 Mio. USD | -0,40 |
| Q3 2025 | 30.09.2025 | 30.10.2025 | 164,9 Mio. USD | 0,28 |
| Q2 2025 | 30.06.2025 | 06.08.2025 | 114,4 Mio. USD | -0,14 |
| Q1 2025 | 31.03.2025 | 01.05.2025 | 81,7 Mio. USD | -0,47 |
| Q3 2024 | 30.09.2024 | 31.10.2024 | 62,9 Mio. USD | -0,70 |
| Q2 2024 | 30.06.2024 | 01.08.2024 | 54,1 Mio. USD | -0,91 |
| Q1 2024 | 31.03.2024 | 06.05.2024 | 41,4 Mio. USD | -1,76 |
| Q3 2023 | 30.09.2023 | 07.11.2023 | 37,1 Mio. USD | 1,97 |
| Q2 2023 | 30.06.2023 | 03.08.2023 | 32,2 Mio. USD | -1,13 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 04.05.2026 | 10-Q | 31.03.2026 | 34 Tage | SEC » |
| 19.02.2026 | 10-K | 31.12.2025 | 50 Tage | SEC » |
| 30.10.2025 | 10-Q | 30.09.2025 | 30 Tage | SEC » |
| 06.08.2025 | 10-Q | 30.06.2025 | 37 Tage | SEC » |
| 01.05.2025 | 10-Q | 31.03.2025 | 31 Tage | SEC » |
| 21.02.2025 | 10-K | 31.12.2024 | 52 Tage | SEC » |
| 31.10.2024 | 10-Q | 30.09.2024 | 31 Tage | SEC » |
| 01.08.2024 | 10-Q | 30.06.2024 | 32 Tage | SEC » |
| 06.05.2024 | 10-Q | 31.03.2024 | 36 Tage | SEC » |
| 20.02.2024 | 10-K | 31.12.2023 | 51 Tage | SEC » |
| 07.11.2023 | 10-Q | 30.09.2023 | 38 Tage | SEC » |
| 03.08.2023 | 10-Q | 30.06.2023 | 34 Tage | SEC » |
| 04.05.2023 | 10-Q | 31.03.2023 | 34 Tage | SEC » |
| 23.02.2023 | 10-K | 31.12.2022 | 54 Tage | SEC » |
| 27.10.2022 | 10-Q | 30.09.2022 | 27 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 05.05.2022 | 10-Q | 31.03.2022 | 35 Tage | SEC » |
| 24.02.2022 | 10-K | 31.12.2021 | 55 Tage | SEC » |
| 29.10.2021 | 10-Q | 30.09.2021 | 29 Tage | SEC » |
| 29.07.2021 | 10-Q | 30.06.2021 | 29 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 01.03.2021 | 10-K | 31.12.2020 | 60 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 31.07.2020 | 10-Q | 30.06.2020 | 31 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 07.05.2026 | Kapitalerhöhung | $475,0 Mio | SEC » |
| 05.05.2026 | Kapitalerhöhung | $400,0 Mio | SEC » |
| 08.11.2024 | Kapitalerhöhung | $125,0 Mio · $16,00/Aktie | SEC » |
| 07.11.2024 | Kapitalerhöhung | – | SEC » |
| 31.10.2024 | Kapitalerhöhung | $100,0 Mio | SEC » |
| 01.03.2023 | Kapitalerhöhung | $188,0 Mio · $21,00/Aktie | SEC » |
| 27.02.2023 | Kapitalerhöhung | $175,0 Mio | SEC » |
| 09.03.2022 | Kapitalerhöhung | $275,0 Mio | SEC » |
| 08.03.2022 | Kapitalerhöhung | $250,0 Mio | SEC » |
| 12.02.2021 | Kapitalerhöhung | $164,7 Mio · $26,75/Aktie | SEC » |
| 10.02.2021 | Kapitalerhöhung | $150,0 Mio | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 06.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 06.04.2026 | HV-Einladung | 19.05.2026 Jahres-HV | 23.03.2026 | DEF 14A | SEC » |
| 01.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 01.04.2025 | HV-Einladung | 15.05.2025 Jahres-HV | 24.03.2025 | DEF 14A | SEC » |
| 27.03.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 27.03.2024 | HV-Einladung | 08.05.2024 Jahres-HV | 20.03.2024 | DEF 14A | SEC » |
| 13.04.2023 | HV-Einladung | 17.05.2023 Jahres-HV | 21.03.2023 | DEF 14A | SEC » |
| 04.04.2022 | HV-Einladung | 11.05.2022 Jahres-HV | 18.03.2022 | DEF 14A | SEC » |
| 16.04.2021 | HV-Einladung | 14.05.2021 Jahres-HV | 23.03.2021 | DEF 14A | SEC » |
| 06.04.2021 | Vorläufig | — | — | PRE 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (09.07.2026)
HOCH Abgang Schlüsselpersonen (16.06.2026)
HOCH Abgang Schlüsselpersonen (21.05.2026)
HOCH Abgang Schlüsselpersonen (09.07.2026)
HOCH Abgang Schlüsselpersonen (16.06.2026)
HOCH Abgang Schlüsselpersonen (21.05.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 09.07.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 21.05.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 17.08.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 of Form 8-K, this Current Report on Form 8-K/A is being filed as an amendment to the Initial Form 8-K to… |
| 12.05.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 20.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 06.01.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 12.10.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 17.09.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.09.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 19.05.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 19.05.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 09.07.2026 | Personalwechsel | 0,00 | 75 | Sandra Calvin, die Chief Accounting Officer (CAO) und Principal Accounting Officer (PAO) von Travere Therapeutics, hat ihre Absicht kundgete… 🔒 | SEC |
| 16.06.2026 | Personalwechsel | -0,25 | 60 | Chief Research Officer William Rote, Ph.D., wird zum 17. Februar 2027 nach 10 Jahren in den Ruhestand treten. Das Unternehmen hat mit der ac… 🔒 | SEC |
| 21.05.2026 | HV-Abstimmung | 0,05 | 45 | Aktionäre genehmigten auf der Hauptversammlung 2026 die Erhöhung der genehmigten Aktien unter dem 2018 Equity Incentive Plan um 3 Millionen … 🔒 | SEC |
| 11.05.2026 | Finanzierung/Anleihe | -0,15 | 60 | Travere Therapeutics gab konvertible Schuldverschreibungen (Convertible Notes) im Wert von $50 Millionen in öffentlichem Angebot aus. Die Un… 🔒 | SEC |
| 04.05.2026 | Quartalszahlen | 0,00 | 55 | Travere Therapeutics veröffentlichte Finanzergebnisse für Q1 2026 (Quartal endete 31. März 2026). | SEC |
| 14.04.2026 | Behördliche Maßnahme | 0,80 | 87 | FDA genehmigte FILSPARI (Sparsentan) zur Behandlung von FSGS in Patienten ab 8 Jahren und erweitert die Anwendung über die ursprüngliche Ind… 🔒 | SEC |
| 19.02.2026 | Quartalszahlen | 0,00 | 70 | Travere Therapeutics gab am 19. Februar 2026 Finanzergebnisse für das vierte Quartal und Geschäftsjahr 2025 bekannt. | SEC |
| 13.01.2026 | Behördliche Maßnahme | -0,35 | 45 | Die FDA verlängert den Review-Prozess für die sNDA von FILSPARI® (sparsentan) zur FSGS-Behandlung bis zum 13. April 2026 nach Einreichung zu… 🔒 | SEC |
| 12.01.2026 | Quartalszahlen | 0,10 | 45 | Travere Therapeutics kündigte am 12. Januar 2026 vorläufige Finanzergebnisse für Q4 und das Geschäftsjahr 2025 an. | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 89.520 | 58,30 | 5.219.016 |
| 2026-06-29 | 31.945 | 58,85 | 1.879.963 |
| 2026-06-26 | 23 | 59,03 | 1.358 |
| 2026-06-23 | 17 | 55,11 | 937 |
| 2026-06-22 | 200 | 55,15 | 11.030 |
| 2026-06-15 | 672 | 52,04 | 34.971 |
| 2026-06-09 | 14.263 | 47,08 | 671.502 |
| 2026-06-08 | 40.947 | 45,81 | 1.875.782 |
| 2026-06-05 | 933 | 46,18 | 43.086 |
| 2026-05-29 | 2.989 | 47,76 | 142.755 |
| 2026-05-19 | 91 | 42,89 | 3.903 |
| 2026-04-28 | 621 | 40,81 | 25.343 |
| 2026-04-27 | 1.305 | 40,50 | 52.853 |
| 2026-04-23 | 517 | 40,09 | 20.727 |
| 2026-04-22 | 4.184 | 38,78 | 162.256 |
| 2026-04-21 | 2.930 | 40,29 | 118.050 |
| 2026-04-20 | 7.615 | 40,77 | 310.464 |
| 2026-04-15 | 59.592 | 42,13 | 2.510.611 |
| 2026-04-14 | 2.439 | 30,70 | 74.877 |
| 2026-04-06 | 74.414 | 30,44 | 2.265.162 |
| 2026-04-02 | 513 | 31,42 | 16.118 |
| 2026-03-24 | 14 | 27,75 | 389 |
| 2026-03-23 | 57 | 26,84 | 1.530 |
| 2026-03-02 | 2.255 | 29,79 | 67.176 |
| 2026-02-25 | 427 | 30,88 | 13.186 |
| 2026-02-06 | 1.229 | 29,47 | 36.219 |